Express Scripts (ESRX) Earning Somewhat Positive News Coverage, Study Finds
Media coverage about Express Scripts (NASDAQ:ESRX) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Express Scripts earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.9296637596179 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s scoring:
- Is The Stock A Good Investment? – Express Scripts Holding Company (NASDAQ: ESRX) – Alpha Beta Stock (alphabetastock.com)
- Zacks: Brokerages Anticipate Express Scripts Holding (ESRX) Will Announce Quarterly Sales of $25.12 Billion (americanbankingnews.com)
- Express Scripts Holding (ESRX) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Optimistic Trending Companies: Juniper Networks, Inc. (JNPR), Express Scripts Holding Company (ESRX) – Market Movers (financialqz.com)
- Super Savings: Inside Rx Expands Its Prescription Savings Program, Offers Discounts on 100 Brand Name Medications (finance.yahoo.com)
ESRX has been the topic of a number of research reports. TheStreet upgraded shares of Express Scripts from a “c+” rating to a “b-” rating in a report on Monday, December 4th. ValuEngine upgraded shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Deutsche Bank initiated coverage on shares of Express Scripts in a report on Monday, December 4th. They set a “buy” rating and a $75.00 target price on the stock. Jefferies Group restated a “buy” rating on shares of Express Scripts in a report on Thursday, October 26th. Finally, Zacks Investment Research upgraded shares of Express Scripts from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a report on Monday, October 16th. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Express Scripts presently has a consensus rating of “Hold” and a consensus target price of $77.09.
Express Scripts (NASDAQ:ESRX) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.90. The firm had revenue of $24.68 billion during the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. Express Scripts’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.74 EPS. equities analysts anticipate that Express Scripts will post 7.04 EPS for the current fiscal year.
Express Scripts declared that its Board of Directors has authorized a share buyback program on Monday, December 18th that allows the company to repurchase 45,000,000 shares. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
In other Express Scripts news, VP Christine Houston sold 10,104 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $70.08, for a total value of $708,088.32. Following the completion of the transaction, the vice president now owns 87,400 shares of the company’s stock, valued at approximately $6,124,992. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Timothy C. Wentworth bought 8,000 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was acquired at an average cost of $61.13 per share, with a total value of $489,040.00. Following the transaction, the chief executive officer now owns 98,628 shares in the company, valued at approximately $6,029,129.64. The disclosure for this purchase can be found here. In the last three months, insiders sold 17,644 shares of company stock valued at $1,289,609. 0.68% of the stock is owned by insiders.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.